TTK Prestige a good contrarian bet: SP Tulsian

TTK Prestige is a good contrarian bet, says SP Tulsian, sptulsian.com.

Tulsian told CNBC-TV18, “Q1 was a big disappointment for TTK Prestige, but I am expecting the company maybe doing much, much better than what they have posted in Q1 and that can make the stock to move back to about Rs 4,000 also.”
He further added, “I am keeping my positive stance, though the market maybe a bit cautious because of the Q1 disappointing numbers. It will be a good idea to take a contrarian view ahead of the results as a long call on the stock.”
“It is difficult to take a general call on the impact of this policy on all the pharma stocks but four stocks come in my mind which can be negatively impacted. One is Lupin, second Cipla, third is Abort and fourth could be Ipca Labs. So four stocks you need to have little cautious view but I don’t think other pharma stocks will really get much impacted by this.”